FECS-Ad is under clinical development by S.Biomedics and currently in Phase II for Critical Limb Ischemia. According to GlobalData, Phase II drugs for Critical Limb Ischemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the FECS-Ad LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FECS-Ad overview
FECS-Ad is under development for the treatment of limb ischemia. The therapy comprises of heterologous adipose stem cells. It is administered through intramuscular route.
S.Biomedics overview
S.Biomedics is a biopharmaceutical company that develops cell therapies for regenerative biomedicine to provide more fundamental and safe treatment solutions for intractable diseases. The company uses functionally enhanced cell spheroid (FECS) and targeted embryonic stem cell differentiation (TED) core platform technologies to develop cell therapy products. Its drug pipeline portfolio includes TED-N, TED-A9, TED-R, TED-N-A, FECS-Ad, FECS-DF, CF-TED-N, and CF-FECS-DF. The company is developing drugs to treat subacute spinal cord injury, parkinson’s disease, macular degeneration, alzheimer’s disease, critical limb ischemia, crow feet, stroke, and wound care. S.Biomedics is headquartered in Seongdong-Gu, Seoul, South Korea.
For a complete picture of FECS-Ad’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
